Publicado 31/05/2014 13:32
- Comunicado -

Ibrutinib Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia (y 3)

        
        Media Inquiries:
        Satu Kaarina Glawe
        Mobile: +49(172)294-6264

        Investor Relations:
        Stan Panasewicz
        Phone: +1-732-524-2524

        Louise Mehrotra
        Phone: +1-732-524-6491

Contenido patrocinado